Partnerships

Agreement with Helmholtz Centre for Infection Research

Posted on
helmholtz collaboration with Pharmacelera

By Melanie Berg – Nov. 30, 2020 Pharmacelera is proud to announce today, that an agreement was reached with Helmholtz Centre for Infection Research (HZI) for a collaboration.   Helmholtz institute for Pharmaceutical Research Saarland (HIPS), which is a branch of the HZI, will utilize PharmScreen®, a field-based high throughput virtual screening software package, to identify […]

News

Agreement with Universitat Autònoma de Barcelona (UAB) in drug discovery for Parkinson disease

Posted on
Pharmacelera agreement with Universitat Autònoma de Barcelona (UAB) in drug discovery for Parkinson disease

The Universitat Autònoma de Barcelona (UAB) and Pharmacelera have reached an agreement to perform a research project in the area of Parkinson based on the work led by Dr. Salvador Ventura and developed at Institut de Biotecnologia i Biomedicina (IBB). PharmScreen®, Pharmacelera’s flagship software, will be used to perform screening campaigns in huge virtual libraries […]

Science

Alignment of PIM-1 Inhibitors with PharmScreen

Posted on

Pim-1 is an oncogene-encoded serine/threonine kinase. Originally identified in Maloney murine leukaemia, it is involved in several cellular functions associated with survival an proliferation which confers a selective advantage during tumorigenesis [1,2]. Given this implication, it has been used as a cancer drug target [3]. IYZ and LY2 are two bioactive inhibitors of Pim-1. The […]